Journal
IMMUNITY
Volume 52, Issue 4, Pages 583-589Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2020.03.007
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract [75N93019C00051]
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract [HHSN272201400008C]
- NIAID grants [AI117287, AI128821]
- U.S. Department of Defense
- Bill and Melinda Gates Foundation
- CEIRS
Ask authors/readers for more resources
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and causedmore than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available